Common variants associated with plasma triglycerides and risk for coronary artery disease

Tanya M. Teslovich | Ross M. Fraser | May E. Montasser | Daniel F. Freitag | Cameron D. Palmer | Martha L. Gravito | J. Danesh | S. Bandinelli | D. Hernandez | C. Gieger | D. Absher | T. Assimes | L. Ferrucci | E. Mihailov | P. Deloukas | D. Strachan | G. Abecasis | K. Stirrups | T. Lehtimäki | U. Thorsteinsdóttir | K. Stefánsson | J. Beckmann | D. Altshuler | E. Boerwinkle | V. Salomaa | M. Perola | C. Wijmenga | C. Lindgren | J. Hirschhorn | L. Groop | M. Laakso | J. O’Connell | M. Boehnke | B. Neale | P. Ridker | D. Chasman | N. Samani | W. McArdle | M. Mangino | P. Munroe | C. Groves | T. Ferreira | V. Gudnason | I. Borecki | A. Chakravarti | A. Hingorani | J. Whitfield | F. Rivadeneira | G. Eyjolfsson | I. Olafsson | G. Thorleifsson | M. Reilly | D. Rader | S. Wild | G. Willemsen | A. Palotie | S. Ripatti | A. Metspalu | T. Esko | D. Gurdasani | R. Nsubuga | E. Young | C. Pomilla | G. Asiki | P. Kaleebu | K. Fischer | E. Ingelsson | C. Meisinger | D. Arveiler | L. Tiret | K. Mohlke | L. Bonnycastle | C. Willer | A. Jackson | A. Swift | J. Saramies | J. Tuomilehto | A. Doney | B. Voight | S. Kathiresan | J. Rotter | N. Klopp | T. Illig | G. Cesana | J. Ordovás | T. Lakka | R. Rauramaa | I. Rudan | D. Boomsma | K. Silander | N. Wareham | I. Surakka | J. Kettunen | A. Isaacs | S. Gustafsson | H. Grallert | A. Hamsten | N. Pedersen | A. Jula | C. Power | M. Järvelin | P. Franks | H. Hólm | J. Lindström | M. Uusitupa | L. Cupples | M. Burnier | C. Palmer | P. Koudstaal | J. Kaprio | R. Do | G. Peloso | D. Saleheen | B. Boehm | B. Wolffenbuttel | L. Waite | J. Kooner | I. Njølstad | T. Wilsgaard | I. Barroso | S. Hunt | T. Johnson | C. Hayward | M. Kaakinen | S. Kanoni | M. Dimitriou | P. Vollenweider | M. Feitosa | P. Komulainen | J. Luan | I. Nolte | A. Stančáková | B. Tayo | Jinghua Zhao | G. Ehret | B. Gigante | G. Hallmans | J. Kuusisto | C. Langenberg | J. Chambers | S. Sanna | P. Meneton | R. Nagaraja | A. Shuldiner | B. Mitchell | R. Strawbridge | S. Vedantam | P. Fontanillas | J. Price | K. Khaw | K. Hveem | E. Tremoli | A. Ganna | Jin Chen | M. Buchkovich | S. Mora | J. Bragg-Gresham | Hsing-Yi Chang | A. Demirkan | L. Donnelly | K. Heikkilä | Å. Johansson | M. Kleber | Xiaohui Li | L. Lyytikäinen | A. Petersen | D. Shungin | C. Sidore | Ci Song | K. Volcik | A. Wong | L. Been | J. Bolton | P. Brambilla | M. Burnett | M. Goodarzi | Y. Hung | Michelle R Jones | J. Kastelein | M. Kumari | Gabrielle Müller | T. Nieminen | A. Pouta | A. Ruokonen | H. Scharnagl | N. Wainwright | F. Bennett | M. Bochud | P. Bovet | A. Feranil | J. Ferrières | G. Hovingh | C. Hsiung | C. Iribarren | A. Kesäniemi | D. Kuh | K. Kyvik | L. Moilanen | P. Pramstaller | T. Quertermous | D. Sanghera | A. Siegbahn | C. Duijn | Yii-DerIda Chen | U. Faire | M. Järvelin | Andrew A. Hicks | G. Dedoussis | L. V. Pelt | R. Saxena | J. Seeley | L. Wallentin | P. Magnusson | Chi Gao | Martin L. Buchkovich | Wayne Huey-Herng Sheu | Shih-Yi Lin | F. Mach | S. Rich | E. V. D. Herik | U. Gyllensten | Xiaohui Li | Steve E. Humphries | P. Franks | R. Saxena | Stephen E. Epstein | Harry Campbell | Linda S. Adair | M. Daly | L. Lind | R. Krauss | James F. Wilson | Winfried März | François Mach | Richard S. Cooper | Paul Elliott | T. Papamarkou | Cameron Palmer | A. Hofman | H. M. Hertog | C. Song | T. Spector | Eric Kim | N. Freimer | S. Bornstein | A. D. Morris | Jing Hua Zhao | Weihua Zhang | M. Kähönen | A. Uitterlinden | Peter E. H. Schwarz | C. McKenzie | Narisu Narisu | K. Ong | Sebanti Sengupta | H. Campbell | T. Harris | Angela Döring | Anna-Liisa Hartikainen | Nick Martin | Sonia Shah | Ellen M. Schmidt | Toshiko Tanaka | B. Psaty | Ying Wu | R. Loos | T. B. Harris | M. Sandhu | Martina Müller-Nurasyid | Elina Hyppönen | M. McCarthy | F. Collins | M. Kivimäki | Andrew Wong | Jerome I. Rotter | Markku Laakso | Andrew D. Morris | Peter E. H. Schwarz | DavidP. Strachan | Ron Do | A. Hofman | Ruth J. F. Loos | Luigi Ferrucci | Carlos Iribarren | Ying Wu | A. Palotie | C. Wijmenga | Jacques S. Beckmann | Kari Stefansson | A. Jackson | Sarah H. Wild | Colin N. A. Palmer | Nancy L. Pedersen | Bruce H. R. Wolffenbuttel | I. Njølstad | Ken K Ong | N. Wareham | Ken K. Ong | Matti Uusitupa | Leif C. Groop | J. Kastelein | Terho Lehtimäki | Steve E Humphries | A. Döring | Daniel J. Rader | Dena G. Hernandez | J. Tuomilehto | Braxton D. Mitchell | B. Neale | P. Elliott | M. Daly | J. Danesh | Anders Hamsten | J. Kaprio | Mark I McCarthy | Jaakko Kaprio | Chi Gao | J. Seeley | L. J. V. Pelt | Jackie F. Price | L. Groop | Johannes Kettunen | Y. I. Chen | Antero Y. Kesäniemi | David P. Strachan | Nicholas G. Martin | L. Ferrucci | Colin N. A. Palmer | Kári Stefánsson | C. Iribarren | G. K. Hovingh | M. Laakso | J. Kaprio | Sarah H Wild | B. H. Wolffenbuttel | M. I. McCarthy | Janet Seeley | P. Fontanillas | T. Lehtimäki | B. Wolffenbuttel | C. Palmer | R. Loos

[1]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[2]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[3]  J. Danesh,et al.  Large-scale association analysis identifies new risk loci for coronary artery disease , 2013 .

[4]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[5]  S. Yusuf,et al.  n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. , 2012, The New England journal of medicine.

[6]  B. Nordestgaard,et al.  LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. , 2012, The Journal of clinical endocrinology and metabolism.

[7]  B. Nordestgaard,et al.  Abstract 16452: LCAT, HDL Cholesterol and Myocardial Infarction - A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals , 2011 .

[8]  N. Mehta.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. , 2011, Circulation. Cardiovascular genetics.

[9]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[10]  R. Frikke-Schmidt,et al.  Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. , 2010, The Journal of clinical endocrinology and metabolism.

[11]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[12]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[13]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[14]  S. Lewis.  Mendelian randomization as applied to coronary heart disease, including recent advances incorporating new technology. , 2010, Circulation. Cardiovascular genetics.

[15]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[16]  B. Nordestgaard,et al.  Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. , 2009, The Journal of clinical endocrinology and metabolism.

[17]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[18]  M. Tobin,et al.  Mendelian Randomisation and Causal Inference in Observational Epidemiology , 2008, PLoS medicine.

[19]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[20]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[21]  S. Ebrahim,et al.  Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? , 2008, Human Genetics.

[22]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[23]  D. Lawlor,et al.  Clustered Environments and Randomized Genes: A Fundamental Distinction between Conventional and Genetic Epidemiology , 2007, PLoS medicine.

[24]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[25]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[26]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[27]  S. Ebrahim,et al.  Mendelian randomization: prospects, potentials, and limitations. , 2004, International journal of epidemiology.

[28]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[29]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[30]  R. Dennis Cook,et al.  Detection of Influential Observation in Linear Regression , 2000, Technometrics.

[31]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[32]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[33]  Alan D. Lopez,et al.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.

[34]  A. Hossain,et al.  A comparative study on detection of influential observations in linear regression , 1991 .

[35]  P. Toth.  LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals , 2012 .

[36]  Avner Schlessinger,et al.  ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI , 2012 .

[37]  A map of human genome variation from population scale sequencing , 2012 .

[38]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[39]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[40]  R. Collins,et al.  Common variants at 30 loci contribute to polygenic dyslipidemia , 2009, Nature Genetics.

[41]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[42]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[43]  P. Freedson,et al.  Scientific Statement From the American Heart Association Guide to the Assessment of Physical Activity: Clinical and Research Applications: A , 2015 .